Biofidelity's mission is to enable the early detection of disease and to improve patient outcomes through the implementation of simple yet ultra-high sensitivity diagnostic assays based on our proprietary biochemistry.
We have developed a novel molecular assay enabling the multiplexed detection of genetic mutations at extremely high sensitivity (<0.1% allele fraction) from tissue or blood samples, without the need for DNA sequencing.
Using standard laboratory instrumentation, our assays are simple, fast, scalable and low-cost, enabling rapid implementation and broad adoption. The simplicity of this technology makes it particularly suited to routine testing applications, including patient monitoring for disease recurrence and developed resistance to therapy, and to early detection of disease.
We have developed a novel molecular assay enabling the multiplexed detection of genetic mutations at extremely high sensitivity (<0.1% allele fraction) from tissue or blood samples, without the need for DNA sequencing.
Using standard laboratory instrumentation, our assays are simple, fast, scalable and low-cost, enabling rapid implementation and broad adoption. The simplicity of this technology makes it particularly suited to routine testing applications, including patient monitoring for disease recurrence and developed resistance to therapy, and to early detection of disease.
Location: United Kingdom, England, Cambridge
Employees: 11-50
Total raised: $59M
Founded date: 2019
Investors 3
| Date | Name | Website |
| 29.03.2022 | Octopus Ve... | octopusven... |
| - | Oxford Inv... | oxfordinve... |
| 20.11.2022 | Perscitus ... | perscitusl... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 04.04.2024 | - | $24M | Octopus Ve... |
| 01.02.2022 | Series A | $23M | - |
| 20.08.2020 | Series A | $12M | - |
Mentions in press and media 12
| Date | Title | Description |
| 06.04.2024 | Biofidelity Secures €22M in Funding: A Game-Changer in Genomic Technology | Cambridge-based Biofidelity, a genomic technology company, has just locked in a hefty €22M in funding, propelling its total funding to a staggering €55.3M. This cash injection, led by key investors like Octopus Ventures and Agilent Technolo... |
| 04.04.2024 | UK’s Biofidelity secures €22M from Octopus Ventures, others: Know more | Read this article in: Cambridge-based Biofidelity, a commercial-stage genomic technology company, announced on Wednesday, April 3, that it has secured $24M (approximately €22M) in a fresh funding round, bringing the total funding raised to ... |
| 03.04.2024 | Biofidelity Raises $24M Funding Round | RESEARCH TRIANGLE PARK, NC, Biofidelity, a revolutionary genomic technology company, completed a financing round totaling $24 million. >> Click here for more funding data on Biofidelity >> To export Biofidelity funding data to ... |
| 03.04.2024 | Biofidelity Raises $24M in Funding | Biofidelity, a Cambridge, UK- and Morrisville, NC-based genomic technology company, raised $24M in funding. Backers included Agilent Technologies, Octopus Ventures, BlueYard Capital, and Longwall Ventures. Led by Dr. Barnaby Balmforth, CEO,... |
| 01.02.2022 | Biofidelity Raises $23M in Series A+ Financing | Biofidelity, a Cambridge UK-based cancer diagnostic company, raised $23M in Series A+ funding. The round was led by Octopus Ventures and backed by SBI Investment Co. Ltd., and existing investors. The company intends to use the funds to expa... |
| 28.07.2021 | Biofidelity opens US headquarters and new cancer diagnostic laboratory | CAMBRIDGE, United Kingdom., July 28, 2021 (GLOBE NEWSWIRE) -- Biofidelity Ltd, the cancer diagnostics company, today announces the opening of its US headquarters in Research Triangle Park, North Carolina, expanding its presence in the key U... |
| 07.04.2021 | Biofidelity granted key patent in US for breakthrough cancer diagnostic technology | CAMBRIDGE, United Kingdom, April 07, 2021 (GLOBE NEWSWIRE) -- Biofidelity Ltd, the cancer diagnostics company, today announced that it has been granted a key patent in the US protecting its underlying technology. The grant of US patent US20... |
| 21.08.2020 | Biofidelity raises $12m in Series A financing to accelerate launch of disruptive cancer diagnostic technology | Biofidelity raises $12m in Series A financing to accelerate launch of disruptive cancer diagnostic technology 21-08-2020 Biofidelity Ltd, a Cambridge cancer diagnostics company, today announces the successful completion of a $12m Series A f... |
| 21.08.2020 | Biofidelity raises $12m in Series A financing to accelerate launch of disruptive cancer diagnostic technology | Biofidelity Ltd, a Cambridge cancer diagnostics company, today announces the successful completion of a $12m Series A financing. The round was led by BlueYard Capital and backed by experienced investors including Longwall Ventures and Agile... |
| 20.08.2020 | UK Cancer Diagnostics Startup Biofidelity Raises $12M | What You Should Know: – UK-based Biofidelity raises $12 million in Series A funding to accelerate the launch of disruptive cancer diagnostic technology. – The funding will be used to bring technology to market, enabling a dramatic simplific... |
Show more